Kiora Pharmaceuticals Inc
7EY
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
169 Saxony Road
Suite 212
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,093.80 | 34.30 | 0.38% |
| CAC 40 | 8,384.01 | 33.14 | 0.40% |
| DAX 40 | 24,894.01 | 258.71 | 1.05% |
| Dow JONES (US) | 51,671.03 | 468.77 | 0.92% |
| FTSE 100 | 10,430.62 | 41.10 | -0.39% |
| HKSE | 24,589.86 | 252.81 | -1.02% |
| NASDAQ | 26,683.94 | 795.10 | 3.07% |
| Nikkei 225 | 69,148.60 | 168.90 | -0.24% |
| NZX 50 Index | 13,386.65 | 26.06 | 0.20% |
| S&P 500 | 7,554.29 | 122.83 | 1.65% |
| S&P/ASX 200 | 8,879.60 | 39.20 | 0.44% |
| SSE Composite Index | 4,087.36 | 9.11 | -0.22% |